新冠疫情争议：托珠单抗篇章 - Suppr

Covid-19 controversies: the tocilizumab chapter.

作者信息

McCreary Erin K, Meyer Nuala J

机构信息

Department of Medicine, Division of Infectious Diseases, UPMC Health System and the University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA

Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

出版信息

BMJ. 2021 Jan 27;372:n244. doi: 10.1136/bmj.n244.

DOI:10.1136/bmj.n244

PMID:33504502

Abstract

摘要

相似文献

Covid-19 controversies: the tocilizumab chapter.

BMJ. 2021 Jan 27;372:n244. doi: 10.1136/bmj.n244.

Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.

Int Immunopharmacol. 2020 Nov;88:106869. doi: 10.1016/j.intimp.2020.106869. Epub 2020 Aug 4.

Tocilizumab in Covid-19.

N Engl J Med. 2021 Jan 7;384(1):86-87. doi: 10.1056/NEJMc2032911. Epub 2020 Dec 22.

Tocilizumab in Covid-19. Reply.

N Engl J Med. 2021 Jan 7;384(1):87. doi: 10.1056/NEJMc2032911. Epub 2020 Dec 22.

Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors' reply.

Pulmonology. 2021 Jan-Feb;27(1):87-88. doi: 10.1016/j.pulmoe.2020.10.003. Epub 2020 Oct 21.

Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report.

J Med Case Rep. 2020 Oct 15;14(1):187. doi: 10.1186/s13256-020-02503-9.

Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.

J Autoimmun. 2020 Nov;114:102523. doi: 10.1016/j.jaut.2020.102523. Epub 2020 Jul 16.

Tocilizumab for COVID-19: a real 'miracle drug'?

Infect Dis (Lond). 2020 Sep;52(9):681-682. doi: 10.1080/23744235.2020.1780307. Epub 2020 Jun 17.

Tocilizumab in COVID-19: Beware the risk of intestinal perforation.

Int J Antimicrob Agents. 2020 Jul;56(1):106009. doi: 10.1016/j.ijantimicag.2020.106009. Epub 2020 May 7.

Use of tocilizumab in multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2.

J Pediatr. 2021 Jan;228:315. doi: 10.1016/j.jpeds.2020.09.054. Epub 2020 Oct 26.

引用本文的文献

Efficacy and safety of interleukin-6 receptor antagonists in adult patients admitted to intensive care unit with COVID-19: A systematic review and -analysis of randomized controlled trials.

Prev Med Rep. 2023 Aug;34:102276. doi: 10.1016/j.pmedr.2023.102276. Epub 2023 Jun 7.

Public perceptions of the association between drug effectiveness and drug novelty in France during the COVID-19 pandemic.

Therapie. 2022 Nov-Dec;77(6):693-701. doi: 10.1016/j.therap.2022.05.001. Epub 2022 May 7.

Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial.

Open Forum Infect Dis. 2021 Dec 4;9(1):ofab608. doi: 10.1093/ofid/ofab608. eCollection 2022 Jan.

The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies.

Front Pharmacol. 2021 Nov 18;12:704205. doi: 10.3389/fphar.2021.704205. eCollection 2021.

Signals were broadly positive for months, but never definitive: the tocilizumab story.

Clin Microbiol Infect. 2022 Mar;28(3):371-374. doi: 10.1016/j.cmi.2021.10.018. Epub 2021 Nov 9.

A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID-19.

Immun Inflamm Dis. 2022 Feb;10(2):201-208. doi: 10.1002/iid3.563. Epub 2021 Nov 11.

Decreased mortality and increased side effects in COVID-19 patients treated with IL-6 receptor antagonists: systematic review and meta-analysis.

Sci Rep. 2021 Nov 2;11(1):21522. doi: 10.1038/s41598-021-00726-4.

Mapping Pulmonary and Systemic Inflammation in Preschool Aged Children With Cystic Fibrosis.

Front Immunol. 2021 Oct 15;12:733217. doi: 10.3389/fimmu.2021.733217. eCollection 2021.

Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study.

PLoS One. 2021 Sep 10;16(9):e0257376. doi: 10.1371/journal.pone.0257376. eCollection 2021.

Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era.

Front Med (Lausanne). 2021 Aug 20;8:706482. doi: 10.3389/fmed.2021.706482. eCollection 2021.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Covid-19 controversies: the tocilizumab chapter.

作者信息

McCreary Erin K, Meyer Nuala J

机构信息

Department of Medicine, Division of Infectious Diseases, UPMC Health System and the University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA

Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

出版信息

BMJ. 2021 Jan 27;372:n244. doi: 10.1136/bmj.n244.

DOI:10.1136/bmj.n244

PMID:33504502

Abstract

摘要

相似文献

Covid-19 controversies: the tocilizumab chapter.

BMJ. 2021 Jan 27;372:n244. doi: 10.1136/bmj.n244.

Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.

Int Immunopharmacol. 2020 Nov;88:106869. doi: 10.1016/j.intimp.2020.106869. Epub 2020 Aug 4.

Tocilizumab in Covid-19.

N Engl J Med. 2021 Jan 7;384(1):86-87. doi: 10.1056/NEJMc2032911. Epub 2020 Dec 22.

Tocilizumab in Covid-19. Reply.

N Engl J Med. 2021 Jan 7;384(1):87. doi: 10.1056/NEJMc2032911. Epub 2020 Dec 22.

Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors' reply.

Pulmonology. 2021 Jan-Feb;27(1):87-88. doi: 10.1016/j.pulmoe.2020.10.003. Epub 2020 Oct 21.

Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report.

J Med Case Rep. 2020 Oct 15;14(1):187. doi: 10.1186/s13256-020-02503-9.

Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.

J Autoimmun. 2020 Nov;114:102523. doi: 10.1016/j.jaut.2020.102523. Epub 2020 Jul 16.

Tocilizumab for COVID-19: a real 'miracle drug'?

Infect Dis (Lond). 2020 Sep;52(9):681-682. doi: 10.1080/23744235.2020.1780307. Epub 2020 Jun 17.

Tocilizumab in COVID-19: Beware the risk of intestinal perforation.

Int J Antimicrob Agents. 2020 Jul;56(1):106009. doi: 10.1016/j.ijantimicag.2020.106009. Epub 2020 May 7.

Use of tocilizumab in multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2.

J Pediatr. 2021 Jan;228:315. doi: 10.1016/j.jpeds.2020.09.054. Epub 2020 Oct 26.

引用本文的文献

Efficacy and safety of interleukin-6 receptor antagonists in adult patients admitted to intensive care unit with COVID-19: A systematic review and -analysis of randomized controlled trials.

Prev Med Rep. 2023 Aug;34:102276. doi: 10.1016/j.pmedr.2023.102276. Epub 2023 Jun 7.

Public perceptions of the association between drug effectiveness and drug novelty in France during the COVID-19 pandemic.

Therapie. 2022 Nov-Dec;77(6):693-701. doi: 10.1016/j.therap.2022.05.001. Epub 2022 May 7.

Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial.

Open Forum Infect Dis. 2021 Dec 4;9(1):ofab608. doi: 10.1093/ofid/ofab608. eCollection 2022 Jan.

The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies.

Front Pharmacol. 2021 Nov 18;12:704205. doi: 10.3389/fphar.2021.704205. eCollection 2021.

Signals were broadly positive for months, but never definitive: the tocilizumab story.

Clin Microbiol Infect. 2022 Mar;28(3):371-374. doi: 10.1016/j.cmi.2021.10.018. Epub 2021 Nov 9.

A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID-19.

Immun Inflamm Dis. 2022 Feb;10(2):201-208. doi: 10.1002/iid3.563. Epub 2021 Nov 11.

Decreased mortality and increased side effects in COVID-19 patients treated with IL-6 receptor antagonists: systematic review and meta-analysis.

Sci Rep. 2021 Nov 2;11(1):21522. doi: 10.1038/s41598-021-00726-4.

Mapping Pulmonary and Systemic Inflammation in Preschool Aged Children With Cystic Fibrosis.

Front Immunol. 2021 Oct 15;12:733217. doi: 10.3389/fimmu.2021.733217. eCollection 2021.

Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study.

PLoS One. 2021 Sep 10;16(9):e0257376. doi: 10.1371/journal.pone.0257376. eCollection 2021.

Front Med (Lausanne). 2021 Aug 20;8:706482. doi: 10.3389/fmed.2021.706482. eCollection 2021.

Covid-19 controversies: the tocilizumab chapter.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Covid-19 controversies: the tocilizumab chapter.

作者信息

机构信息

出版信息

相似文献

引用本文的文献